Companies › Eilean Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ZE63-0302 | – | Phase 1 | Type 2 Diabetes | Nov 2026 |
| ZE94-0605 Selective cyclin-dependent kinase 2 (CDK2) inhibitor | CDK2 | Phase 1 | Advanced Solid Tumor Cancer | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07234864 | ZE63-0302 | Phase 1 | Type 2 Diabetes | Metabolic and endocrine | Nov 2026 |
| NCT07524140 | ZE94-0605 | Phase 1 | Advanced Solid Tumor Cancer | Oncology | Jan 2028 |
NiKang Therapeutics Avenzo Therapeutics Chia Tai Tianqing Pharmaceutical Group BeiGene AstraZeneca Incyclix Bio
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.